MedTrace Logo

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany

NCT02450812 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2021-11-02

No results posted yet for this study

Summary

This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

Radium-223-dichloride (Xofigo, BAY88-8223)

according to Summary of Product Characteristics

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-28
Primary Completion
2020-06-30
Completion
2020-09-17

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450812 on ClinicalTrials.gov